ETFChannel.com
HZNP Description — Horizon Therapeutics Plc

Horizon Therapeutics is focused on researching, developing and commercializing medicines that address needs for rare and rheumatic diseases. Co.'s segments are: Orphan, which includes Co.'s marketed medicines KRYSTEXXA® (pegloticase injection) for intravenous infusion, RAVICTI® (glycerol phenylbutyrate) oral liquid, PROCYSBI® (cysteamine bitartrate) delayed-release capsules for oral use, and ACTIMMUNE® (interferon gamma-1b) injection for subcutaneous use; and Inflammation, which includes Co.'s marketed medicines PENNSAID® (diclofenac sodium topical solution) 2% w/w, DUEXIS® (ibuprofen/famotidine) tablets, and VIMOVO® (naproxen/esomeprazole magnesium) delayed-release tablets, for oral use.

Company Name: 
Horizon Therapeutics Plc
Website: 
www.horizontherapeutics.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding HZNP: 
74
Total Market Value Held by ETFs: 
$2,757,550,255.09
Total Market Capitalization: 
$23,960,000,000
% of Market Cap. Held by ETFs: 
11.51%
 ETF   HZNP Weight   HZNP Amount 
 VTI   0.05%   $689,057,389         
 VO   0.34%   $546,182,635         
 VXF   0.30%   $352,024,288         
 VUG   0.11%   $189,169,047         
 VOT   0.65%   $158,412,690         
 USMV   0.47%   $134,217,752         
 VHT   0.38%   $72,572,899         
 IWR   0.21%   $62,710,515         
 XBI   0.75%   $54,733,700         
 IWD   0.09%   $51,057,876         
List of all 74 ETFs holding HZNP »
Quotes delayed 20 minutes

Strong Buy (3.94 out of 4)
72nd percentile
(ranked higher than approx. 72% of all stocks covered)

Analysts Forecast:
HZNP Price Target

Based on data provided by Zacks Investment Research via Quandl.com

ETFs Holding HZNP | Horizon Therapeutics Plc | ETF Channel | www.ETFChannel.com

Copyright © 2010 - 2021, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.